J. Raskin

J. Nelson, P. Liu, Peng Liu, 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Safety and Tolerability of Duloxetine at 60 mg Once Daily in Elderly Patients With Major Depressive Disorder

C. Katona, J. Raskin, D. Desaiah, 2008, Journal of clinical psychopharmacology.

An In Vitro Analysis of Disintegration Times of Different Formulations of Olanzapine Orodispersible Tablet: A Preliminary Report

T. Treuer, J. Raskin, D. Hobbs, 2013, Drugs in R&D.

Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo

Y. Gao, Q. Li, G. Yang, 2015, International journal of clinical practice.

Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.

L. Marangell, J. Raskin, R. E. Granger, 2012, Journal of psychiatric research.

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.

T. Le, J. Wernicke, S. Iyengar, 2006, Current therapeutic research, clinical and experimental.

Hypersensitivity disorder and vernacular science.

D. Stewart, J. Raskin, D. Stewart, 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Management of depression relapse: re-initiation of duloxetine treatment or dose increase.

M. Fava, M. Detke, M. Balestrieri, 2006, Journal of psychiatric research.

The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity

D. Iosifescu, J. Raskin, T. Wise, 2007, International journal of clinical practice.

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features

C. Mallinckrodt, Chaofeng Liu, J. Raskin, 2005, BMC psychiatry.

Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.

C. Mallinckrodt, J. Raskin, M. Sullivan, 2009, Psychosomatics.

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.

Smriti Iyengar, J. Wernicke, S. Iyengar, 2006, Journal of palliative medicine.

Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies

C. Katona, J. Greist, P. Liu, 2013, International clinical psychopharmacology.

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

J. Krege, J. Raskin, Simin K. Baygani, 2019, Cephalalgia : an international journal of headache.

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine

J. Krege, J. Raskin, Rashmi B Halker Singh, 2019, Cephalalgia : an international journal of headache.

Anorexia nervosa, bulimia, and pregnancy.

D. Stewart, P. Garfinkel, J. Raskin, 1987 .

Rapid tranquilization with olanzapine in acute psychosis: a case series.

J. Raskin, J. Karagianis, I. Dawe, 2001, The Journal of clinical psychiatry.

The frequency and severity of symptoms of major depression in Chinese patients with chronic, medically unexplained, painful physical symptoms who present to a general neurology clinic

Dong Zhou, J. Jia, Liyong Wu, 2011 .

Association between Painful Physical Symptoms and Clinical Outcomes in Korean Patients with Major Depressive Disorder: A Three-Month Observational Study

T. Treuer, V. Reed, J. Raskin, 2009, Psychiatry investigation.

Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

J. Raskin, Y. Pritchett, D. Desaiah, 2006, International clinical psychopharmacology.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

M. Thase, M. Bauer, J. Russell, 2008, Journal of psychiatric research.

Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint.

M. Pollack, J. Russell, S. Kornstein, 2008, Journal of psychiatric research.

Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain

J. Raskin, R. Tanenberg, G. Irving, 2014, International journal of clinical practice.

The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder.

M. Fava, L. Marangell, J. Raskin, 2014, Comprehensive psychiatry.

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder

D. Kajdasz, A. Tylee, J. Raskin, 2006, International journal of clinical practice.

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

R. Mohs, J. Sheikh, A. Siegal, 2007, The American journal of psychiatry.

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

R. Heine, Dara L. Schuster, D. Kendall, 2015, Diabetes Therapy.

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

M. Case, J. Krege, J. Raskin, 2019, Cephalalgia : an international journal of headache.

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

J. Krege, S. Dowsett, J. Raskin, 2019, Headache.

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible‐dose, progressive‐titration, placebo‐controlled trial

Moira Rynn, James Russell, J. Erickson, 2008, Depression and anxiety.

Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder

D. Kajdasz, J. Raskin, J. Xu, 2008, International Psychogeriatrics.

Meta-analyses and antidepressant prescribing

J. Raskin, W. Deberdt, A. Lenox-Smith, 2010, Journal of psychopharmacology.

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

M. Case, J. Krege, S. Dowsett, 2019, BMC Neurology.

Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease.

E. Siemers, J. Cummings, R. Mohs, 2016, The journal of prevention of Alzheimer's disease.

COGNITIVE IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE

E. Siemers, R. Mohs, P. Aisen, 2014, Alzheimer's & Dementia.

Anorexia nervosa, bulimia, and pregnancy

J. Raskin, P. Garfinkel, D. Stewart, 1988, American journal of obstetrics and gynecology.

Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil

Xiufeng Xu, J. Raskin, Min-Soo Lee, 2007, Psychiatry and Clinical Neurosciences.

Association between painful physical symptoms and clinical outcomes in Taiwanese patients with major depressive disorder: A three‐month observational study

C. Yeh, N. Chiu, J. Raskin, 2010, Chinese medical journal.

Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms.

O. Brawman‐Mintzer, J. Raskin, C. Wiltse, 2007, Psychiatry (Edgmont (Pa. : Township)).

Duloxetine in the long-term treatment of major depressive disorder.

C. Mallinckrodt, D. Goldstein, J. Raskin, 2003, The Journal of clinical psychiatry.

Weight Gain Risk Factor assessment checklist: overview and recommendation for use.

I. Lipkovich, T. Treuer, H. Lockman, 2011, Neuro endocrinology letters.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

K. Demyttenaere, S. Brecht, J. Raskin, 2007, The Journal of clinical psychiatry.

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

R. Shelton, M. Detke, C. Mallinckrodt, 2007, International clinical psychopharmacology.

Association between painful physical symptoms and clinical outcomes in East Asian patients with major depressive disorder: a 3‐month prospective observational study

Y. Wing, J. Raskin, A. Sulaiman, 2009, International journal of clinical practice.

Frequency and outcomes of painful physical symptoms in a naturalistic population with major depressive disorder: an analysis of pooled observational studies focusing on subjects aged 65 years and over

J. Raskin, A. Brnabic, E. Serap Monkul, 2012, International journal of clinical practice.

Patterns of depressive symptom response in duloxetine‐treated outpatients with mild, moderate or more severe depression

R. Shelton, M. Detke, C. Mallinckrodt, 2007, International journal of clinical practice.

Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine

D. Sheehan, J. Raskin, P. Chokka, 2011, Human psychopharmacology.

Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics

D. Kajdasz, J. Raskin, D. Walker, 2006, International clinical psychopharmacology.

Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period

Arier C. Lee, A. Montejo, J. Raskin, 2011, International journal of psychiatry in clinical practice.

Attributes of response in depressed patients switched to treatment with duloxetine

J. Raskin, R. E. Granger, D. Sagman, 2011, International journal of clinical practice.

Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trial.

J. Nelson, Peng Liu, J. Raskin, 2013, The primary care companion for CNS disorders.

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies

J. Erickson, J. Davidson, M. Pollack, 2008, Human psychopharmacology.

Major depressive disorder severity and the frequency of painful physical symptoms: a pooled analysis of observational studies

E. Monkul, J. Raskin, A. Brnabic, 2012, Current Medical Research and Opinion.

The integral inventory for depression, a new, self-rated clinimetric instrument for the emotional and painful dimensions in major depressive disorder

C. Lara, J. Raskin, M. Dossenbach, 2011, International journal of psychiatry in clinical practice.

Suicidal thoughts and reasons for living in hospitalized patients with severe depression: post-hoc analyses of a double-blind randomized trial of duloxetine.

K. Demyttenaere, V. Cairns, S. Brecht, 2014, The primary care companion for CNS disorders.

P.2.c.008 Apathy in SSRI-treated patients with depression: outcomes after switch to duloxetine or escitalopram

L. Marangell, J. Raskin, R. E. Granger, 2011, European Neuropsychopharmacology.

Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies

C. Katona, J. Greist, Peng Liu, 2013, International clinical psychopharmacology.